Clinical pharmacology guidance for antiviral treatment of COVID-19
The clinical pharmacology guidance for antiviral treatment of COVID-19 was compiled by the Guangdong Pharmaceutical Association. It is based on the latest research results at home and abroad, and combined with the experience of COVID-19 rescue in Guangdong Province. The guidance provides detailed instructions on the clinical pharmacology applications of nirmatrelvir/ritonavir, bamlanivimab/etesevimab, intravenous COVID-19 human immunoglobulin and convalescent plasma, in order to promote the rational clinical application of antiviral drugs for COVID-19, effectively improve the level of drug treatment, and ensure patient safety.
